UA43797A - Injection form of the preparation, which manifests the anti-ischemic activity - Google Patents

Injection form of the preparation, which manifests the anti-ischemic activity

Info

Publication number
UA43797A
UA43797A UA99020840A UA99020840A UA43797A UA 43797 A UA43797 A UA 43797A UA 99020840 A UA99020840 A UA 99020840A UA 99020840 A UA99020840 A UA 99020840A UA 43797 A UA43797 A UA 43797A
Authority
UA
Ukraine
Prior art keywords
preparation
manifests
triphosphat
adenosin
injection form
Prior art date
Application number
UA99020840A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Віктор Петрович Георгієвський
Виктор Петрович Георгиевский
Ала Георгієвна Піотровська
Алла Георгиевна Петровская
Наталія Петрівна Хованська
Наталья Петровна Хованская
Віктор Павлович Кутняк
Виктор Павлович Кутняк
Петро Андрійович Манорик
Петр Андреевич Манорик
Георгій Миколайович Ліпкан
Георгий Николаевич Липкан
Original Assignee
Акціонерне Товариство Закритого Типу "Фармацевтична Фірма "Фаркос"
Акционерное Общество Закрытого Типа "Фармацевтическая Фирма "Фаркос"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Акціонерне Товариство Закритого Типу "Фармацевтична Фірма "Фаркос", Акционерное Общество Закрытого Типа "Фармацевтическая Фирма "Фаркос" filed Critical Акціонерне Товариство Закритого Типу "Фармацевтична Фірма "Фаркос"
Priority to UA99020840A priority Critical patent/UA43797A/en
Priority to RU99105304/14A priority patent/RU2190411C2/en
Publication of UA43797A publication Critical patent/UA43797A/en

Links

Abstract

The injection form of preparation on basis adenosin -5'-triphosphat in the isotonic solution, that manifests anti-ischemic activity is described. As the source of adenosin -5'-triphosphat it contains tripotassium salt adenosin -5'-triphosphat histidinatomagnesium (II) octahydrate and additionally contains pharmaceutical acceptable organic either inorganic acid or their salts in the quantity necessary for achievement of pH 7,0-7,4.
UA99020840A 1999-02-15 1999-02-15 Injection form of the preparation, which manifests the anti-ischemic activity UA43797A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
UA99020840A UA43797A (en) 1999-02-15 1999-02-15 Injection form of the preparation, which manifests the anti-ischemic activity
RU99105304/14A RU2190411C2 (en) 1999-02-15 1999-03-18 Injectional form of preparation of antiischemic activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UA99020840A UA43797A (en) 1999-02-15 1999-02-15 Injection form of the preparation, which manifests the anti-ischemic activity

Publications (1)

Publication Number Publication Date
UA43797A true UA43797A (en) 2001-12-17

Family

ID=21689331

Family Applications (1)

Application Number Title Priority Date Filing Date
UA99020840A UA43797A (en) 1999-02-15 1999-02-15 Injection form of the preparation, which manifests the anti-ischemic activity

Country Status (2)

Country Link
RU (1) RU2190411C2 (en)
UA (1) UA43797A (en)

Also Published As

Publication number Publication date
RU2190411C2 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
IL144026A0 (en) Phenylphenanthridine derivatives and pharmaceutical compostions containing the same
TW376319B (en) Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
YU23599A (en) Stabilized antihistamine syrup
DE191133T1 (en) STABLE SALT FROM SAM WITH POLYANIONS.
JO3404B1 (en) Liquid pharmaceutical composition containing an erythropoietin derivative
HK1053603A1 (en) Medicament based on gestagens for dermal application comprising ascorbic acid and/or salts thereof
MXPA02001254A (en) Moxifloxacin formulation containing common salt.
MY130441A (en) Solutions containing epinastin
EP0787497A3 (en) Pharmaceutical preparation containing human growth hormone
TR200002605T2 (en) Halogenated amidino amino acid derivatives useful as nitric oxide synthase inhibitors
RS50445B (en) Pharmaceutical solutions of levosimendan
BG105257A (en) New oral formulation for 5-ht4 agonists or antagonists
DE69818261D1 (en) Hydroxycyclopentanone
AR245591A1 (en) Oral rinse compositions
HUP9801712A2 (en) Pharmaceutical compositions containing cilansetron stabilized against racemisation, their production and use of stobilizing additive agents
DE69901506T2 (en) USE OF SODIUM CHLORIDE TO REDUCE THE GASTROINTESTINAL TOXICITY OF CAMPTOTECINE DERIVATIVES.
UA43797A (en) Injection form of the preparation, which manifests the anti-ischemic activity
NO20013544D0 (en) Means for treating Parkinson's disease and its use
DE10299023I1 (en) Active substance with an antineoplastic effect and which enhances the antineoplastic effect
EP0489925A4 (en) Pyrimidine compound and pharmaceutically acceptable salt thereof
DE69627519D1 (en) SESQUITERPEN DERIVATIVES WITH ANTIVIRAL ACTIVITY
YU46302A (en) Substituted pyrroles
PL1603559T3 (en) Pharmaceutical composition for intracellular acidification with cis-urocanic acid
DE69815347D1 (en) tetrahydrofuran derivatives
ZA939604B (en) Imidazole derivatives